[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638445":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":47,"collaborators":49,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":78,"whyStopped":20,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Poznan University of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Type 2 diabetes","EXPERIMENTAL","Pregnant patients with type 2 diabetes treated with automated insulin delivery system",[13],"Device: Automated insulin delivery system - Medtronic 780G",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Automated insulin delivery system - Medtronic 780G","Use of automated insulin delivery system in pregnant patients with type 2 diabetes",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Ewa Wender-Ozegowska, Prof. MD PhD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","+48 (61) 841-93-02","ewozegow@ump.edu.pl",[31],{"facility":32,"status":20,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Heliodor Swiecicki Clinical Gynecology and Obstetrics Hospital of Poznan University of Medical Sciences","Poznan","Wielkopolska","60-535","Poland","PL",{"type":39,"coordinates":40},"Point",[41,42],16.92993,52.40692,{"lat":42,"lon":41},[45,46],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":48,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[50],{"name":51,"class":52},"Medtronic","INDUSTRY","100638445","type-2-diabetes-and-pregnancy-a-single-arm-interventional-study-100638445",false,"NCT07602036","Type 2 Diabetes and Pregnancy a Single-arm Interventional Study","pUMPreg2","Inclusion Criteria:\n\n1. Women with diagnosed pregestational type 2 diabetes or HbA1c \\>6.5% in the 1st trimester (ADA, PTD)\n2. Age 18-45 years\n3. Gestational age of 16 weeks +0 days or less at baseline\n4. Singleton pregnancy\n5. HbA1c at baseline 5.0-10%\n6. A viable pregnancy at the recruitment\n7. Willingness to continue the treatment until delivery in the clinic\n\nExclusion Criteria:\n\n1. Other types of diabetes including T1D and Monogenic diabetes\n2. Major fetal congenital defects\n3. Severe nephropathy, psychiatric illness or other serious medical disorder that in the judgment of the investigator could affect completion of the trial\n4. Pump therapy before pregnancy","FEMALE","18 Years","45 Years",{"count":64,"type":65},20,"ESTIMATED","INTERVENTIONAL",[68],"NA","This single-arm interventional study evaluates the MiniMed 780G insulin pump and continuous glucose monitoring (CGM) system in pregnant women with type 2 diabetes enrolled at ≤ 16 weeks gestation. From recruitment to delivery, participants attend regular clinical visits for active insulin adjustments. The primary objective is to measure the percentage of time spent in the target pregnancy glucose range (63-140 mg\u002FdL). Secondary outcomes track mean glucose, HbA1c, and overall maternal and neonatal health to ensure safety and efficacy.",[71,72],"Pregnancy","Type 2 Diabetes",[74,75,76,77],"type 2 diabetes","pregnancy","insulin pump","Automated insulin delivery system","NOT_YET_RECRUITING","2026-05-15",{"date":81,"type":82},"2026-05-22","ACTUAL",{"date":84,"type":65},"2026-05-01",{"date":86,"type":65},"2029-02",{"name":5,"class":6},1]